The present disclosure provides crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine (A2-73), in freebase or salt forms. Also described are pharmaceutical formulations and dosage forms comprising the disclosed crystal forms, and methods of using crystalline A2-73 in dosage forms for neuroprotection including treatment of neurodegenerative and other diseases.
本公开提供了自由基或盐形式的四氢-N,N-二甲基-2,2
-二苯基-3-
呋喃甲胺(A2-73)的晶体形式。还描述了包括所述晶体形式的制药配方和剂型,以及使用晶体A2-73的剂型进行神经保护的方法,包括治疗神经退行性和其他疾病。